V enous thromboembolism, which includes deep vein thrombosis and pulmonary embolus, is a life-threatening complication for hospitalised patients. Compared to the general population, cancer patients are at a fourfold increase in the frequency of venous thromboembolism, and as high as a sixfold increase during chemotherapy (Heit et al, 2000). Cancer-associated venous thromboembolism is prevalent, with the rate increasing by 28% from 1995 to 2003, with an overall venous thromboembolism incident rate of 4.1%, with 3.4% being deep vein thrombosis and 1.1% being pulmonary embolus, in a recent analysis of 1 000 000 hospitalised cancer patients (Khorana et al, 2007). These patients also have significantly worse chances of survival (Sørensen et al, 2000; Auer et al, 2012), suffering from higher rates of complications of bleeding and recurrent venous thromboembolism (Sørensen et al, 2000, Prandoni et al, 2002Khorana et al, 2007). The mortality rate for pulmonary embolus following a deep vein thrombosis ranges from 5% to 37% in untreated patients and is about 6% among patients treated after diagnosis with anticoagulation (Wilson and Murray, 2005).In a previous study by Ng et al (2017), it was reported that 5.2% of cancer patients were affected with venous thromboembolism during the course of rehabilitation. Patients who were found to have lower extremity oedema at admission (P=0.02) had Calf measurements screening for deep vein thrombosis in acute inpatient cancer rehabilitation